Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Initial stabilization
Airway protection triggers
Repeated emesis with inability to protect airway
Depressed mental status with aspiration risk
Breathing support triggers
Hypoxemia with aspiration pneumonia concern
Severe metabolic acidosis with respiratory fatigue
Circulation targets
Mean arterial pressure 65 mmHg or higher
Urine output 0.5 mL/kg/hour or higher
Early escalation triggers
Hypotension
Shock
Toxic megacolon concern
Ileus with distension and pain
Infection control at triage
Contact precautions
Gown and gloves
Dedicated equipment
Hand hygiene
Soap and water preferred when spores concern
Alcohol gel as adjunct, not replacement
Environmental cleaning
Sporicidal disinfectant
High touch surface focus
Complication screen
Fulminant disease features
Hypotension or shock
Ileus
Toxic megacolon
Dehydration and electrolyte derangement risk
Volume depletion
Hypokalemia risk
Acute kidney injury risk
Sepsis physiology
Lactate elevation
Altered mental status
Peripheral hypoperfusion
Severity classification
Severity categories
Nonsevere criteria
White blood cell count 15 x 10^9/L or less
Serum creatinine less than 1.5 mg/dL equivalent local baseline threshold
Severe criteria
White blood cell count greater than 15 x 10^9/L
Serum creatinine 1.5 mg/dL equivalent or higher relative to baseline
Fulminant criteria
Hypotension
Shock
Ileus
Toxic megacolon
High risk recurrence profile
Age 65 years or older
Immunocompromised state
Prior C difficile episode within 6 months
Severe initial presentation
Concomitant systemic antibiotic requirement
Key decision points
Early consult and activation
If fulminant features, ICU and surgery consultation
Toxic megacolon concern
Perforation concern
If severe dehydration or AKI, inpatient admission planning
Persistent tachycardia
Orthostasis
If refractory pain or distension, imaging pathway
CT abdomen pelvis for complication assessment
Antimicrobial stewardship actions
Inciting antibiotic stop or narrow
If clinically feasible, stop high risk antibiotics
If ongoing need, select narrowest effective agent
Gastric acid suppression review
Proton pump inhibitor continuation only with clear indication
Test strategy
Stool testing eligibility
Unformed stool with diarrhea
New onset unexplained diarrhea
Avoid low value testing
Formed stool testing avoidance
Test of cure avoidance
History
Presentation profile
Typical syndrome
Diarrhea pattern
Three or more unformed stools in 24 hours
Watery stools
Associated symptoms
Lower abdominal cramping
Fever
Nausea
Systemic impact
Lightheadedness
Decreased urine output
Atypical presentations
Ileus predominant
Minimal diarrhea
Abdominal distension
Fulminant physiology
Confusion
Syncope
Severe abdominal pain
Exposure and risk factors
Medication triggers
Systemic antibiotic exposure within prior 8 to 12 weeks
Clindamycin exposure
Fluoroquinolone exposure
Cephalosporin exposure
Broad spectrum beta lactam exposure
Proton pump inhibitor exposure
Recent chemotherapy or immunosuppressants
Healthcare exposure
Recent hospitalization
Long term care residence
Recent emergency department visit
Host risk factors
Age 65 years or older
Inflammatory bowel disease
Solid organ or stem cell transplant
Chronic kidney disease
Course modifiers
Episode characterization
First episode
Recurrent episode
Symptom return within 2 to 8 weeks after resolution
Multiple recurrences
Two or more recurrences
Severity signals
Reduced oral intake
Bloody stool
Marked abdominal distension
Decreased bowel sounds
Prior CDI therapies
Fidaxomicin exposure
Oral vancomycin exposure
Vancomycin taper history
Prior fecal microbiota therapy
Physical Exam
General and hemodynamics
Hemodynamic profile
Tachycardia
Persistent heart rate elevation after fluids
Hypotension
Systolic blood pressure below baseline
Orthostatic changes
Symptomatic dizziness on standing
Volume status
Dry mucous membranes
Poor skin turgor
Delayed capillary refill
Mental status
Delirium
Lethargy
Abdominal exam
Abdominal findings
Diffuse tenderness
Lower quadrant tenderness
Distension
Tympany
Peritoneal signs
Guarding
Rebound tenderness
Rigidity
Ileus signals
Hypoactive bowel sounds
Absent bowel sounds
Toxic megacolon concern
Marked distension
Severe tenderness
Fever with systemic toxicity
PITFALLS
Misleading exam patterns
Minimal diarrhea with ileus
Reliance on diarrhea frequency alone misses fulminant cases
Abdominal pain out of proportion
Consider ischemia or perforation alternative diagnosis
Afebrile severe disease
Immunocompromised blunted fever response
Differential Diagnosis
Infectious causes
Alternative infectious colitis
Norovirus gastroenteritis
Abrupt vomiting prominent
Salmonella enterocolitis
Fever with inflammatory diarrhea
Campylobacter enterocolitis
Bloody diarrhea and cramping
Shigella enterocolitis
Tenesmus
Shiga toxin producing E coli
HUS risk profile
Giardia
Greasy stools and bloating
Noninfectious causes
Inflammatory and ischemic
Ulcerative colitis flare
Chronic history and hematochezia
Crohn colitis flare
Weight loss and chronicity
Ischemic colitis
Sudden pain with bloody stool in vascular risk
Medication and toxin
Laxative associated diarrhea
Osmotic exposure history
Metformin related diarrhea
Dose change temporal link
Surgical emergencies
Appendicitis
Localized right lower quadrant pain
Bowel obstruction
Obstipation and vomiting
Perforated viscus
Free air concern
Coding aligned diagnoses
ICD-10 and SNOMED CT mapping
ICD-10 A04.7 enterocolitis due to Clostridioides difficile
SNOMED CT Clostridioides difficile colitis
ICD-10 K52.9 noninfective gastroenteritis and colitis unspecified
SNOMED CT colitis
Laboratory Tests
Core labs
Baseline assessment
Complete blood count for leukocytosis and hemoconcentration
White blood cell count severity marker
Anemia for alternative diagnosis or bleeding
Electrolytes for dehydration complications
Sodium derangement risk
Potassium depletion risk
Creatinine for AKI and severity classification
Baseline comparison importance
Systemic toxicity assessment
Lactate for hypoperfusion and fulminant physiology
Rising lactate escalation trigger
C reactive protein for inflammatory burden
Trend support in severe cases
Hepatic panel when severe illness
Albumin for prognostic risk
Low albumin associated with severe course
Stool studies
CDI testing eligibility prerequisites
Unformed stool sampling
Bristol stool types 6 to 7 surrogate
New onset diarrhea without clear alternate cause
Laxative exposure exclusion when applicable
CDI diagnostic assays
NAAT for toxigenic C difficile genes
High sensitivity
Colonization positive risk
Toxin A B enzyme immunoassay
Lower sensitivity than NAAT
Higher specificity for active toxin production
GDH antigen assay
Sensitive screen for C difficile organism
Requires confirmatory toxin or NAAT
Additional stool tests by phenotype
Stool culture or multiplex PCR for inflammatory diarrhea alternative
Fever and bloody stool pattern
Ova and parasite for prolonged watery diarrhea
Travel and exposure risk
Pitfalls and limitations
Common lab interpretation errors
Test of cure misuse
Persistent NAAT positivity after clinical resolution
Formed stool testing
High false positive colonization signal
Concurrent laxatives
Diarrhea attribution error
Diagnostic Tests
Scoring Systems
Severity frameworks
IDSA severity categorization
Nonsevere criteria
White blood cell count 15 x 10^9/L or less
Serum creatinine less than 1.5 mg/dL equivalent local baseline threshold
Severe criteria
White blood cell count greater than 15 x 10^9/L
Serum creatinine 1.5 mg/dL equivalent or higher relative to baseline
Fulminant criteria
Hypotension
Shock
Ileus
Toxic megacolon
Recurrence risk stratifiers
Age 65 years or older
Increased recurrence risk
Immunocompromised state
Higher relapse and complications
Severe initial episode
Higher recurrence probability
Toxic megacolon criteria support
Radiographic colonic dilation
Colon diameter 6 cm or greater as typical threshold
Systemic toxicity features
Fever
Tachycardia
Leukocytosis
MRI
Limited role
Indications
Pregnancy with complication concern and CT avoidance preference
Contrast allergy with severe concern when ultrasound nondiagnostic
Constraints
Limited availability in acute unstable patient
Motion artifact in severe pain
Findings support
Colitis pattern
Complication screening
CT
Imaging indications
Severe abdominal pain or distension
Ileus concern
Megacolon concern
Fulminant physiology
Shock or hypotension
Rising lactate
Alternative diagnosis concern
Ischemic colitis
Perforation
Typical CT findings
Colonic wall thickening
Segmental or pancolitis pattern
Pericolonic stranding
Inflammatory change
Accordion sign supportive
Contrast trapped between edematous haustra
Complications
Toxic megacolon dilation
Pneumoperitoneum
Abscess uncommon
Evidence labeling for ED practice
ACEP Level C recommendation for CT in suspected complications
Imaging use guided by severity and complication concern
Ultrasound
Bedside applications
Volume assessment adjunct
IVC collapsibility context dependent
Lung ultrasound for aspiration pneumonia screening
Bowel ultrasound supportive findings
Colonic wall thickening
Reduced peristalsis in ileus
Limitations
Gas and distension reduce quality
Not a rule out test for megacolon or perforation
Evidence labeling for ED practice
ACEP Level C for ultrasound as adjunct only
Not definitive for CDI diagnosis
Disposition
Level of care decisions
Admission indications
Severe disease criteria
White blood cell count greater than 15 x 10^9/L
Creatinine elevated from baseline
Fulminant disease criteria
Hypotension
Ileus
Toxic megacolon concern
Inability to maintain oral hydration
Persistent vomiting
Significant orthostasis
High risk host profile with limited supports
Frailty
Immunocompromised state
ICU indications
Shock
Vasopressor requirement
Toxic megacolon
Worsening distension
Rising lactate despite resuscitation
Tissue hypoperfusion concern
Discharge eligibility
Nonsevere criteria with stability
Normal blood pressure
Adequate oral intake
Reliable follow up and access to medications
Same day pharmacy access
No complication red flags
No severe abdominal pain
No distension progression
Consultation and transfer
Specialty involvement triggers
Infectious diseases
Multiple recurrences
Complex immunosuppression
Gastroenterology
Diagnostic uncertainty with possible IBD flare
Fecal microbiota therapy pathway
Surgery
Toxic megacolon concern
Perforation concern
Clinical deterioration despite therapy
Transfer considerations
Need for urgent colectomy capability
Fulminant disease progression
Need for ICU bed
Vasopressor support
Treatment
General measures
Supportive care
Fluid resuscitation
Isotonic crystalloid boluses for hypovolemia
Reassessment targets
Mean arterial pressure 65 mmHg or higher
Urine output 0.5 mL/kg/hour or higher
Electrolyte repletion
Potassium replacement for hypokalemia
Magnesium replacement when low
Avoid antimotility agents in suspected severe colitis
Toxic megacolon risk amplification
Source control and stewardship
Inciting antibiotic discontinuation when feasible
Early stop reduces ongoing microbiome disruption
Acid suppression reduction when feasible
PPI continuation only with clear indication
Evidence labeling for ED actions
ACEP Level C recommendation for early fluids and complication screening in severe diarrhea syndromes
ED consensus practice alignment
Initial episode regimens
Nonsevere or severe initial episode therapy
Fidaxomicin preferred regimen
Fidaxomicin 200 mg PO
Every 12 hours
Duration 10 days
Class I recommendation aligned with guideline preferred first line for initial CDI when available
Oral vancomycin alternative regimen
Vancomycin 125 mg PO
Every 6 hours
Duration 10 days
Class I recommendation aligned with guideline first line option
Metronidazole role limitation
Metronidazole 500 mg PO
Every 8 hours
Duration 10 days
Class IIb recommendation only when fidaxomicin and vancomycin unavailable
Fulminant disease regimen
Fulminant CDI therapy bundle
Oral or NG vancomycin high dose
Vancomycin 500 mg PO or NG
Every 6 hours
Continue until clinical improvement or definitive surgical decision
Class I recommendation for fulminant CDI
Rectal vancomycin if ileus
Vancomycin 500 mg per rectum
In 100 mL normal saline retention enema
Every 6 hours
Rectal administration monitoring
Rectal irritation
Leakage risk with poor retention
Intravenous metronidazole adjunct
Metronidazole 500 mg IV
Every 8 hours
Class I recommendation adjunct when ileus or severe systemic toxicity
Early surgical pathway
If shock or megacolon, urgent surgery consult
Subtotal colectomy with end ileostomy consideration
Diverting loop ileostomy with colonic lavage consideration
Recurrent CDI regimens
First recurrence options
Fidaxomicin standard regimen
Fidaxomicin 200 mg PO
Every 12 hours
Duration 10 days
Fidaxomicin extended pulsed regimen option
Fidaxomicin 200 mg PO
Every 12 hours for 5 days
Then every 48 hours for 20 days
Vancomycin taper and pulse option
Vancomycin 125 mg PO
Every 6 hours for 10 to 14 days
Then every 12 hours for 7 days
Then daily for 7 days
Then every 48 to 72 hours for 2 to 8 weeks
Multiple recurrences options
Fecal microbiota therapy pathway
After appropriate antibiotic course completion
Recurrent episode count two or more typical threshold
Rifaximin chaser option after vancomycin
Rifaximin 400 mg PO
Every 8 hours
Duration 20 days
Class IIb recommendation in selected recurrent cases
Adjunctive recurrence prevention
Bezlotoxumab
Indications
High recurrence risk profile
Age 65 years or older
Immunocompromised state
Severe CDI
Prior CDI within 6 months
Dosing
Bezlotoxumab 10 mg/kg IV
Single dose during antibiotic therapy course
Infusion monitoring
Hypersensitivity reaction
Heart failure exacerbation risk in predisposed patients
Evidence labeling
Class IIa recommendation for recurrence risk reduction in high risk patients
Monitoring and response
Clinical response tracking
Stool frequency trend
Improvement expected within 48 to 72 hours
Abdominal distension trend
Worsening triggers imaging and surgery reassessment
Laboratory trend
White blood cell count trajectory
Creatinine trajectory
Lactate trajectory
Treatment failure triggers
Persistent or worsening hypotension
ICU escalation
Increasing abdominal pain or peritoneal signs
CT and surgical pathway
Rising lactate
Sepsis management pathway
Special Populations
Pregnancy
Pregnancy considerations
Diagnostic approach
Stool testing unchanged
Imaging avoidance preference
Ultrasound adjunct when complications suspected
MRI consideration when CT avoidance preferred and stable
Medication safety
Oral vancomycin minimal systemic absorption
Preferred when fidaxomicin access limited
Fidaxomicin limited pregnancy data
Risk benefit discussion and specialist involvement
Metronidazole pregnancy use context
Use when benefits outweigh risks in severe disease
Obstetric coordination triggers
Dehydration with uterine irritability
Preterm labor symptoms
Geriatric
Older adult considerations
Higher severity and recurrence risk
Age 65 years or older risk categorization
Frailty and dehydration vulnerability
Medication and adverse event monitoring
Renal function monitoring with volume depletion
Delirium risk with infection and dehydration
Disposition bias
Lower threshold for admission
Home supports assessment
Pediatrics
Pediatric considerations
Colonization nuance
Infants high asymptomatic colonization prevalence
Testing avoidance in infants with alternative explanation likely
Testing appropriateness
Symptomatic diarrhea with risk factors and no alternative cause
Unformed stool requirement
Weight based therapy framework
Oral vancomycin weight based dosing per local pediatric guideline
Fidaxomicin pediatric use per age and weight approvals
Complication vigilance
Toxic megacolon rare but possible
Dehydration rapid progression risk
Background
Epidemiology
Population burden
Leading cause of healthcare associated infectious diarrhea
Hospital and long term care clustering
Community associated CDI increasing recognition
Antibiotic exposure not always present
Recurrence frequency
Recurrence common after first episode
Risk increases with each recurrence
High risk exposures
Broad spectrum antibiotics
Clindamycin high association
Fluoroquinolone association
Healthcare contact
Recent hospitalization
Long term care residence
Pathophysiology
Mechanism
Microbiome disruption
Reduced colonization resistance after antibiotics
Toxin mediated injury
Toxin A and toxin B epithelial damage
Neutrophilic inflammation
Pseudomembrane formation
Fibrin and inflammatory exudate plaques
Disease spectrum
Mild watery diarrhea
Limited systemic toxicity
Severe colitis
Marked inflammation and dehydration
Fulminant colitis
Ileus and megacolon
Perforation risk
Therapeutic Considerations
First line antibiotic selection rationale
Fidaxomicin
Narrow spectrum relative to broad agents
Lower recurrence rates in studies compared with vancomycin
Oral vancomycin
Effective luminal concentrations
Standard alternative when fidaxomicin unavailable
Metronidazole limitations
Inferior outcomes in severe disease
Reserved for access limitations or adjunct IV in fulminant disease
Recurrence prevention rationale
Bezlotoxumab
Monoclonal antibody against toxin B
Reduces recurrence risk in selected high risk groups
Fecal microbiota therapy
Restores microbiome diversity
High efficacy in multiple recurrences
Patient Discharge Instructions
copy discharge instructions
Home care
Hydration plan
Frequent small volumes of oral fluids
Oral rehydration solution preference when significant diarrhea
Medication adherence
Complete full antibiotic course
Do not share medications
Infection prevention at home
Handwashing with soap and water after bathroom use
Separate bathroom if possible
Bleach based cleaning of bathroom surfaces if available
Return to emergency department now
Severe abdominal pain
Worsening tenderness
Abdominal swelling or distension
New inability to pass stool or gas
Blood in stool
New or increasing
Signs of dehydration
Dizziness or fainting
Minimal urine output
Persistent vomiting
Unable to keep fluids down
Fever with worsening symptoms
Chills and weakness
Confusion or severe weakness
New trouble staying awake
Follow up plan
Primary care or clinic follow up within 48 to 72 hours if not improving
Review symptoms and hydration status
Medication access confirmation
Pharmacy pickup same day when possible
Recurrence awareness
Return of diarrhea after improvement merits reassessment
References
Clinical guidelines and key evidence
Guideline sources
IDSA and SHEA focused update for Clostridioides difficile infection management
Fidaxomicin preferred for initial and recurrent CDI in many patients
Fulminant CDI regimen includes high dose oral vancomycin plus IV metronidazole
American College of Gastroenterology guideline for CDI
Multistep testing strategy support
Fecal microbiota therapy for multiple recurrences
CDC CDI clinical overview and infection control guidance
Contact precautions and environmental cleaning emphasis
Evidence trials and adjuncts
Bezlotoxumab randomized trial evidence base for recurrence reduction
Benefit concentrated in high risk recurrence groups
Fidaxomicin vs vancomycin trials
Similar initial cure with lower recurrence for fidaxomicin in studies
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.